INOVIO Reports FDA Partial Clinical Hold for Planned Phase 2 / 3 Trial of COVID-19 Vaccine Candidate INO-4800

PLYMOUTH MEETING, Pa., Sept. 28, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials